Intensity Therapeutics, Inc., a late-stage clinical biotechnology company, engages in the provision of treatment for the regional and systemic nature of cancer relapse and metastasis in the United States. Its lead product candidate includes INT230-6, which is in Phase 3 clinical studies for the treatment of soft tissue sarcoma; and neoadjuvant and metastatic triple negative breast cancer which is in Phase 2 clinical trials. The company was incorporated in 2012 and is headquartered in Shelton, Connecticut. Show more

1 Enterprise Drive, Shelton, CT, 06484-4779, United States

Biotechnology

Healthcare

Market Cap

12.41M

52 Wk Range

$4.50 - $43.50

Previous Close

$4.59

Open

$4.56

Volume

7,498

Day Range

$4.53 - $4.66

Enterprise Value

2.128M

Cash

10.25M

Avg Qtr Burn

-1.826M

Insider Ownership

4.56%

Institutional Own.

6.19%

Qtr Updated

03/31/26

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
INT230-6 Details Advanced Soft tissue sarcomas	Phase 3 Re-initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
INT230-6 Details Neoadjuvant Triple-negative breast cancer	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
INT230-6 (Intratumoral Cytotoxic) Details Metastatic Or Refractory Advanced Solid Tumors	Phase 1/2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.